Towards patient-based cancer therapeutics
Open Access
- 1 September 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 28 (9), 904-906
- https://doi.org/10.1038/nbt0910-904
Abstract
Orienting cancer drug discovery to the patient requires relating the genetic features of tumors to acquired gene and pathway dependencies and identifying small-molecule therapeutics that target them.Keywords
This publication has 23 references indexed in Scilit:
- Probing the Probes: Fitness Factors For Small Molecule ToolsCell Chemical Biology, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesionsJCI Insight, 2009
- Mouse models of human AML accurately predict chemotherapy responseGenes & Development, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver CancerCell, 2008
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences of the United States of America, 2007
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic ApproachCell, 2006